Protagonist Therapeutics (PTGX) Accounts Payables (2015 - 2026)
Protagonist Therapeutics (PTGX) posted Accounts Payables of $8.4 million for Q1 2026, up 58.03% sequentially from $5.3 million in Q4 2025, and up 189.24% YoY from $2.9 million in Q1 2025.
Protagonist Therapeutics (PTGX) Accounts Payables (2015 - 2026) Analysis & Trends
Protagonist Therapeutics has reported Accounts Payables for 12 years, with the latest figure at $8.4 million in Q1 2026.
- Quarterly Accounts Payables rose 189.24% year-over-year to $8.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.4 million (up 189.24% YoY) and the FY2025 annual result came in at $5.3 million, up 230.59% from the prior year.
- Accounts Payables rose to $8.4 million in Q1 2026 per PTGX's latest filing, from $5.3 million in the prior quarter.
- Over five years, Accounts Payables peaked at $8.4 million in Q1 2026 and troughed at $772000.0 in Q4 2023.
- A 5-year average of $3.8 million and a median of $3.6 million in 2024 frame the typical range for Accounts Payables.
- The widest YoY moves for Accounts Payables: up 567.85% in 2022, down 82.14% in 2022.
- Over 5 years, Accounts Payables stood at $3.6 million in 2022, then sank by 78.79% to $772000.0 in 2023, then soared by 109.2% to $1.6 million in 2024, then surged by 230.59% to $5.3 million in 2025, then jumped by 58.03% to $8.4 million in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $8.4 million, $5.3 million, and $5.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Protagonist Therapeutics | 10.03 Bn | 10.03 Bn | - | 3.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.46 Mn |
| Mar 31, 2026 | 8.44 Mn |
| Dec 31, 2025 | 5.34 Mn |
| Sep 30, 2025 | 5.65 Mn |
| Jun 30, 2025 | 3.25 Mn |
| Mar 31, 2025 | 2.92 Mn |
| Dec 31, 2024 | 1.62 Mn |
| Sep 30, 2024 | 3.05 Mn |
| Jun 30, 2024 | 3.63 Mn |
| Mar 31, 2024 | 3.51 Mn |
| Dec 31, 2023 | 772,000.00 |
| Sep 30, 2023 | 1.25 Mn |
| Jun 30, 2023 | 4.57 Mn |
| Mar 31, 2023 | 4.02 Mn |
| Dec 31, 2022 | 3.64 Mn |
| Sep 30, 2022 | 4.72 Mn |
| Jun 30, 2022 | 1.41 Mn |
| Mar 31, 2022 | 7.16 Mn |
| Dec 31, 2021 | 1.60 Mn |
| Sep 30, 2021 | 706,000.00 |